CClinicalTrials.gg
CompletedNCT05162430Updated Dec 17, 2021

Inhibitory Effect of Propofol on Perineal Pruritus in Patients Undergoing Day Surgery

An interventional study of Propofol in Pruritus Vulvae, sponsored by Yangzhou University. Completed at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Yangzhou University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2021, registered Dec 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

OBJECTIVE: To investigate the inhibitory effect of different doses of propofol on perineal pruritus induced by dexamethasone sodium phosphate injection in women, with a view to providing clinical reference for comfortable clinical care in day surgery.

METHODS: One hundred and fifty patients with ASA classification I or II undergoing elective day surgery were randomly divided into six groups of P1, P2, P3, P4, P5 and D1, with 25 cases in each group. Before administration of dexamethasone, propofol injection 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg and 0.5 mg/kg were given intravenously in groups P1, P2, P3, P4 and P5, respectively (injection rate was 5 s), followed by 30 s of intravenous dexamethasone sodium phosphate 10 mg in all five groups; 5 ml of saline was given in group D1, and 30 s After that, dexamethasone sodium phosphate injection was given (injection speed was 5s in all five groups). The perineal itching, the onset and duration of itching, the visual analogue score (VAS) of itching, the sleep disorder sedation score (Ramsay score) and the occurrence of adverse reactions were recorded in the five groups.

02

Conditions studied

  • Pruritus Vulvae

Browse trials for

03

In context

Pruritus

354 studies on the registry are indexed under Pruritus; 74 are open to participants now.

This study's enrollment of 150 is above the median of 60 across 294 interventional studies indexed under Pruritus.

Browse Pruritus studies →

Lead sponsor

Yangzhou University is the lead sponsor of 40 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

Age 18-65 years old ASA classification I-II grade Body mass index (BMI) 18-30kg/m2

Exclusion criteria

Exclusion Criteria:

Patients with paresthesia or pruritus Drug and alcohol abuse Allergies to lipid drugs and contraindications; corticosteroids are cautious Patients Hyperlipidemia Patients during pregnancy and lactation Mental diseases, communication disorders Patients who use hormones for a long time

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    P1 group

    Administration of 0.1 mg/kg of propofol and 5mg dexamethasone phosphate sodium

    Drug: Propofol

  • Experimental
    P2 group

    Administration of 0.2mg/kg of propofol and 5mg dexamethasone phosphate sodium

    Drug: Propofol

  • Experimental
    P3 group

    Administration of 0.3mg/kg of propofol and 5mg dexamethasone phosphate sodium

    Drug: Propofol

  • Experimental
    P4 group

    Administration of 0.4 mg/kg of propofol and 5mg dexamethasone phosphate sodium

    Drug: Propofol

  • Experimental
    P5 group

    Administration of 0.5mg/kg of propofol and 5mg dexamethasone phosphate sodium

    Drug: Propofol

  • No intervention
    D1 group

    Administration of 5mg dexamethasone phosphate sodium

Interventions

  • DrugPropofol

    0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s

06

What researchers measure

Primary outcomes

  1. Duration of pruritus

    After the administration of dexamethasone sodium phosphate, if pruritus occurs, record the beginning and end

    Time frame: 3-6 minutes

  2. Incidence of pruritus

    Calculation of the occurrence of pruritus in each group.

    Time frame: 3-6 minutes

  3. Severity of pruritus

    Pruritus is classified as mild to moderate to severe according to the VAS score.

    Time frame: 3-6 minutes

  4. VAS score

    Patients rate their pruritus according to the VAS scale.

    Time frame: 10-30 seconds

  5. Ramsay score

    Scoring of patients according to their mental status after administration of propofol.

    Time frame: 10-30 seconds

Secondary outcomes

  1. Adverse reactions

    Hypotension, respiratory depression, injection pain after propofol use, record it.

    Time frame: 3-6 minutes

07

Study locations

1 site
  • Liu meiyu
    Yangzhou, Jiangsu 225000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05162430
Lead sponsor
Yangzhou University
Responsible party
Wang wanxia (student, Yangzhou University) — Principal investigator
First posted
Dec 17, 2021
Start date
Jan 20, 2021
Primary completion
Dec 3, 2021
Completion
Dec 4, 2021
Last update
Dec 17, 2021

Study contacts

Liu m yu, Director
principal investigator · Yangzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion